FDA Orange Book · active-ingredient family
Fingolimod lauryl sulfate
Fingolimod lauryl sulfate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:TASCENSO ODT · NDA 214962
1
Brand (NDA)
0
Generics (ANDA)
3
Listed patents
0
Exclusivity periods
Brand (NDA) products · tablet, orally disintegrating
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| TASCENSO ODTRLD×2 | CYCLE | NDA 214962 | — | Dec 23, 2021 |
Listed patents (3)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10555902 | Jan 19, 2036 | in 9 yr 9 mo | U-3268 |
| 9925138 | Jan 19, 2036 | in 9 yr 9 mo | Product |
| 10925829 | Jan 19, 2036 | in 9 yr 9 mo | Product |
Fingolimod lauryl sulfate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
